Zoe Kopp, MD

Title(s)Clinical Fellow, Medicine
SchoolSchool of Medicine
Address1545 Divisadero Street
San Francisco CA 94115
Phone415-353-7900
ORCID ORCID Icon0000-0002-5058-4492 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Emory School of Medicine, Atlanta, GAMD05/2018Medicine
    University of California, San Francisco, San Francisco, CA06/2021Internal Medicine Residency

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Discharge Communication: A Multi-Institutional Survey of Internal Medicine Residents' Education and Practices. Acad Med. 2021 07 01; 96(7):1043-1049. Trivedi SP, Kopp Z, Tang AJ, Mammen A, Pandya D, Horwitz LI, Schwartz MD. PMID: 33332907.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    2. Who is Responsible for Discharge Education of Patients? A Multi-Institutional Survey of Internal Medicine Residents. J Gen Intern Med. 2021 06; 36(6):1568-1575. Trivedi SP, Kopp Z, Williams PN, Hupp D, Gowen N, Horwitz LI, Schwartz MD. PMID: 33532957; PMCID: PMC8175511.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Looking to the Future: Medical Students' Views on Health Care Reform and Professional Responsibility. Acad Med. 2019 09; 94(9):1361-1368. Rook JM, Winkelman TNA, Fox JA, Pierce JB, Oot AR, Blum JR, Feuerbach AM, Shahu A, Goldman ML, Kopp Z, Duffy E, Robledo-Gil T, Tran N, Davey CS, Henschen BL. PMID: 31460934; PMCID: PMC6663659.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    4. Development of an overactive bladder assessment tool (BAT): A potential improvement to the standard bladder diary. Neurourol Urodyn. 2018 06; 37(5):1701-1710. Kelleher C, Chapple C, Johnson N, Payne C, Homma Y, Hakimi Z, Siddiqui E, Evans C, Egan S, Kopp Z. PMID: 29360189.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. A Narrative Review of Patient-reported Outcomes in Overactive Bladder: What is the Way of the Future? Eur Urol. 2016 11; 70(5):799-805. Chapple CR, Kelleher CJ, Evans CJ, Kopp Z, Siddiqui E, Johnson N, Mako M. PMID: 27160948.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    6. Reliability, validity, and interpretation of the dependence scale in mild to moderately severe Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2013 Dec; 28(8):738-49. Lenderking WR, Wyrwich KW, Stolar M, Howard KA, Leibman C, Buchanan J, Lacey L, Kopp Z, Stern Y. PMID: 24363071.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    7. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology. 2012 Jul; 80(1):90-6. Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. PMID: 22748867.
      View in: PubMed   Mentions: 84     Fields:    Translation:Humans
    8. LUTS patient reported outcomes tool: linguistic validation in 10 European languages. Neurourol Urodyn. 2013 Jan; 32(1):75-81. Brandt BA, Angün Ç, Coyne KS, Doshi S, Bavendam T, Kopp ZS. PMID: 22674460.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. What are the best outcome measures when assessing treatments for LUTD?--achieving the most out of outcome evaluation: ICI-RS 2011. Neurourol Urodyn. 2012 Mar; 31(3):400-3. Cotterill N, Goldman H, Kelleher C, Kopp Z, Tubaro A, Brubaker L. PMID: 22415657.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    10. Moving towards a comprehensive assessment of lower urinary tract symptoms (LUTS). Neurourol Urodyn. 2012 Apr; 31(4):448-54. Coyne KS, Barsdorf AI, Thompson C, Ireland A, Milsom I, Chapple C, Kopp ZS, Bavendam T. PMID: 22396308.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    11. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies. BJU Int. 2012 Aug; 110(3):392-400. Kelleher CJ, Dmochowski RR, Berriman S, Kopp ZS, Carlsson M. PMID: 22129365.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study. Urology. 2012 Jan; 79(1):95-101. Coyne KS, Margolis MK, Kopp ZS, Kaplan SA. PMID: 22055692.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    13. Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States. Eur Urol. 2012 Jan; 61(1):88-95. Coyne KS, Kvasz M, Ireland AM, Milsom I, Kopp ZS, Chapple CR. PMID: 21831517.
      View in: PubMed   Mentions: 92     Fields:    Translation:Humans
    14. The psychometric validation of a 1-week recall period for the OAB-q. Int Urogynecol J. 2011 Dec; 22(12):1555-63. Coyne KS, Gelhorn H, Thompson C, Kopp ZS, Guan Z. PMID: 21739328.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    15. The placebo effect in overactive bladder syndrome. Nat Rev Urol. 2011 Jul 05; 8(9):495-503. Mangera A, Chapple CR, Kopp ZS, Plested M. PMID: 21727941.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    16. The impact of OAB on sexual health in men and women: results from EpiLUTS. J Sex Med. 2011 Jun; 8(6):1603-15. Coyne KS, Sexton CC, Thompson C, Kopp ZS, Milsom I, Kaplan SA. PMID: 21492396.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    17. Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaire. Int Urogynecol J. 2011 Aug; 22(8):937-46. Brubaker L, Khullar V, Piault E, Evans CJ, Bavendam T, Beach J, Yeh Y, Kopp ZS, Kelleher CJ, Trocio J. PMID: 21373818.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    18. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011 Nov; 108(9):1459-71. Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, Chapple C. PMID: 21371240.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    19. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011 May; 77(5):1081-7. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. PMID: 21256571.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    20. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011 Oct; 108(7):1132-8. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. PMID: 21231991.
      View in: PubMed   Mentions: 262     Fields:    Translation:Humans
    21. The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder. BJU Int. 2011 Jan; 107(2):254-61. Coyne KS, Cash B, Kopp Z, Gelhorn H, Milsom I, Berriman S, Vats V, Khullar V. PMID: 20590548.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    22. Dynamic progression of overactive bladder and urinary incontinence symptoms: a systematic review. Eur Urol. 2010 Oct; 58(4):532-43. Irwin DE, Milsom I, Chancellor MB, Kopp Z, Guan Z. PMID: 20573443.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    23. Can we predict which patient will fail drug treatment for overactive bladder? A think tank discussion. Neurourol Urodyn. 2010 Apr; 29(4):652-7. Nitti VW, Kopp Z, Lin AT, Moore KH, Oefelein M, Mills IW. PMID: 20432330.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    24. Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int. 2009 Apr; 103 Suppl 3:24-32. Coyne KS, Kaplan SA, Chapple CR, Sexton CC, Kopp ZS, Bush EN, Aiyer LP, EpiLUTS Team. PMID: 19302499.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    25. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int. 2009 Apr; 103 Suppl 3:12-23. Sexton CC, Coyne KS, Kopp ZS, Irwin DE, Milsom I, Aiyer LP, Tubaro A, Chapple CR, Wein AJ, EpiLUTS Team. PMID: 19302498.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    26. Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms. BJU Int. 2009 Apr; 103 Suppl 3:48-57. Kaplan SA, Roehrborn CG, Chapple CR, Rosen RC, Irwin DE, Kopp Z, Aiyer LP, Mollon P. PMID: 19302502.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    27. The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU Int. 2009 Apr; 103 Suppl 3:33-41. Wein AJ, Coyne KS, Tubaro A, Sexton CC, Kopp ZS, Aiyer LP. PMID: 19302500.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    28. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009 Apr; 103 Suppl 3:4-11. Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, Aiyer LP. PMID: 19302497.
      View in: PubMed   Mentions: 127     Fields:    Translation:Humans
    29. Rationale for the study methods and design of the epidemiology of lower urinary tract symptoms (EpiLUTS) study. BJU Int. 2009 Aug; 104(3):348-51. Coyne KS, Sexton CC, Kopp ZS, Luks S, Gross A, Irwin D, Milsom I, EpiLUTS Team. PMID: 19291251.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    30. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009 Aug; 104(3):352-60. Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, Chapple CR, Kaplan S, Tubaro A, Aiyer LP, Wein AJ. PMID: 19281467.
      View in: PubMed   Mentions: 206     Fields:    Translation:Humans
    31. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol. 2009 Jul; 56(1):14-20. Irwin DE, Milsom I, Kopp Z, Abrams P, Artibani W, Herschorn S. PMID: 19278775.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansPHPublic Health
    32. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009 Mar; 15(4 Suppl):S98-S107. Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE, Wagner TH. PMID: 19355804.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    33. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health Qual Life Outcomes. 2009 Feb 18; 7:13. Van Kerrebroeck PE, Kelleher CJ, Coyne KS, Kopp Z, Brodsky M, Wang JT. PMID: 19226471; PMCID: PMC2649907.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    34. The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 2009 Jan; 103(2):202-9. Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. PMID: 19278532.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    35. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med. 2008 Dec; 5(12):2904-10. Irwin DE, Milsom I, Reilly K, Hunskaar S, Kopp Z, Herschorn S, Coyne KS, Kelleher CJ, Artibani W, Abrams P. PMID: 19090944.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    36. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int. 2008 Jul; 102(1):56-61. Kelleher CJ, Tubaro A, Wang JT, Kopp Z. PMID: 18564231.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    37. Lower urinary tract symptoms in women-a common but neglected problem. J Am Acad Nurse Pract. 2008 Jun; 20(6):311-8. Bradway C, Coyne KS, Irwin D, Kopp Z. PMID: 18588658.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    38. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008 Jun; 101(11):1388-95. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. PMID: 18454794.
      View in: PubMed   Mentions: 216     Fields:    Translation:Humans
    39. Psychometric equivalence of the OAB-q in Danish, German, Polish, Swedish, and Turkish. Value Health. 2008 Dec; 11(7):1096-101. Coyne KS, Margolis MK, Thompson C, Kopp Z. PMID: 18489500.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    40. Cluster analysis and lower urinary tract symptoms in men: findings from the Boston Area Community Health Survey. BJU Int. 2008 May; 101(10):1247-56. Cinar A, Hall SA, Link CL, Kaplan SA, Kopp ZS, Roehrborn CG, Rosen RC. PMID: 18419698.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    41. Do urological symptoms cluster among women? Results from the Boston Area Community Health Survey. BJU Int. 2008 May; 101(10):1257-66. Hall SA, Cinar A, Link CL, Kopp ZS, Roehrborn CG, Kaplan SA, Rosen RC. PMID: 18419699.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    42. Examining lower urinary tract symptom constellations using cluster analysis. BJU Int. 2008 May; 101(10):1267-73. Coyne KS, Matza LS, Kopp ZS, Thompson C, Henry D, Irwin DE, Artibani W, Herschorn S, Milsom I. PMID: 18336611.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    43. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int. 2008 Jun; 101(11):1381-7. Irwin DE, Abrams P, Milsom I, Kopp Z, Reilly K, EPIC Study Group. PMID: 18336602.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    44. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol. 2008 May; 53(5):1029-37. Irwin DE, Milsom I, Kopp Z, Abrams P, EPIC Study Group. PMID: 18243515.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    45. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire. Neurourol Urodyn. 2008; 27(3):179-90. Piault E, Evans CJ, Espindle D, Kopp Z, Brubaker L, Abrams P. PMID: 17565727.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    46. It's just the worry about not being able to control it! A qualitative study of living with overactive bladder. Br J Health Psychol. 2008 May; 13(Pt 2):343-59. Nicolson P, Kopp Z, Chapple CR, Kelleher C. PMID: 17535499.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    47. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006 Dec; 50(6):1306-14; discussion 1314-5. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. PMID: 17049716.
      View in: PubMed   Mentions: 614     Fields:    Translation:HumansPHPublic Health
    48. Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006 Aug; 176(2):627-32; discussion 632. Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. PMID: 16813906.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    49. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology. 2006 Aug; 68(2 Suppl):3-8. Brubaker L, Chapple C, Coyne KS, Kopp Z. PMID: 16908335.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    50. The current and future burden and cost of overactive bladder in five European countries. Eur Urol. 2006 Nov; 50(5):1050-7. Reeves P, Irwin D, Kelleher C, Milsom I, Kopp Z, Calvert N, Lloyd A. PMID: 16753252.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    51. Translating overactive bladder questionnaires in 14 languages. Urology. 2006 Mar; 67(3):536-40. Acquadro C, Kopp Z, Coyne KS, Corcos J, Tubaro A, Choo MS, Oh SJ. PMID: 16527574.
      View in: PubMed   Mentions: 34     Fields:    
    52. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006 Jun; 49(6):1079-86. Coyne KS, Matza LS, Kopp Z, Abrams P. PMID: 16460875.
      View in: PubMed   Mentions: 95     Fields:    Translation:Humans
    53. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006 Jan; 97(1):96-100. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. PMID: 16336336.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    54. ME Cares: a statewide system engaging providers in disease management. Dis Manag. 2004; 7(2):136-52. Wexler R, Bean C, Ito D, Kopp Z, LaCasse JA, Rea V. PMID: 15228798.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    55. A pharmacoeconomic evaluation of results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES) in Norway and Canada. Int J Cardiol. 2002 Jul; 84(1):23-30; discussion 30-2. Thaulow E, Jorgensen B, Doyle JJ, Casciano R, Casciano J, Kopp Z, Arikian S, Kim R. PMID: 12104059.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    56. Effect of a standardized nurse case-management telephone intervention on resource use in patients with chronic heart failure. Arch Intern Med. 2002 Mar 25; 162(6):705-12. Riegel B, Carlson B, Kopp Z, LePetri B, Glaser D, Unger A. PMID: 11911726.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCTClinical Trials
    57. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press. 2002; 11(1):35-45. Hansson L, Lloyd A, Anderson P, Kopp Z. PMID: 11926349.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    Zoe's Networks
    Concepts (197)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (2)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.1.0-871-g21b54b14 on PROFILES-PWEB02.

    Copyright © The Regents of the University of California